1. Home
  2. FLR vs STVN Comparison

FLR vs STVN Comparison

Compare FLR & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluor Corporation

FLR

Fluor Corporation

HOLD

Current Price

$42.98

Market Cap

6.9B

Sector

Industrials

ML Signal

HOLD

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$19.42

Market Cap

5.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLR
STVN
Founded
1912
1949
Country
United States
Italy
Employees
N/A
N/A
Industry
Military/Government/Technical
Containers/Packaging
Sector
Industrials
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
5.4B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FLR
STVN
Price
$42.98
$19.42
Analyst Decision
Buy
Hold
Analyst Count
7
2
Target Price
$49.57
$23.75
AVG Volume (30 Days)
2.8M
294.8K
Earning Date
02-17-2026
03-05-2026
Dividend Yield
N/A
0.32%
EPS Growth
1235.20
19.61
EPS
20.04
0.60
Revenue
$15,587,000,000.00
$1,373,219,524.00
Revenue This Year
N/A
$8.42
Revenue Next Year
$5.15
$9.61
P/E Ratio
$2.19
$33.04
Revenue Growth
N/A
6.97
52 Week Low
$29.20
$17.81
52 Week High
$57.50
$28.00

Technical Indicators

Market Signals
Indicator
FLR
STVN
Relative Strength Index (RSI) 49.01 35.90
Support Level $43.56 $20.19
Resistance Level $45.25 $21.23
Average True Range (ATR) 1.34 0.76
MACD 0.11 -0.07
Stochastic Oscillator 59.00 8.13

Price Performance

Historical Comparison
FLR
STVN

About FLR Fluor Corporation

Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $16.3 billion in revenue in 2024.

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Share on Social Networks: